These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 24976394)

  • 21. A randomized, double-blind, placebo-controlled pilot study of naltrexone in outpatients with bipolar disorder and alcohol dependence.
    Brown ES; Carmody TJ; Schmitz JM; Caetano R; Adinoff B; Swann AC; John Rush A
    Alcohol Clin Exp Res; 2009 Nov; 33(11):1863-9. PubMed ID: 19673746
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quetiapine in bipolar disorder and cocaine dependence.
    Brown ES; Nejtek VA; Perantie DC; Bobadilla L
    Bipolar Disord; 2002 Dec; 4(6):406-11. PubMed ID: 12519101
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder.
    DelBello MP; Chang K; Welge JA; Adler CM; Rana M; Howe M; Bryan H; Vogel D; Sampang S; Delgado SV; Sorter M; Strakowski SM
    Bipolar Disord; 2009 Aug; 11(5):483-93. PubMed ID: 19624387
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study.
    Bauer M; Pretorius HW; Constant EL; Earley WR; Szamosi J; Brecher M
    J Clin Psychiatry; 2009 Apr; 70(4):540-9. PubMed ID: 19358791
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomised, placebo-controlled studies.
    Vieta E; Mullen J; Brecher M; Paulsson B; Jones M
    Curr Med Res Opin; 2005 Jun; 21(6):923-34. PubMed ID: 15969892
    [TBL] [Abstract][Full Text] [Related]  

  • 26. First controlled treatment trial of bipolar II hypomania with mixed symptoms: quetiapine versus placebo.
    Suppes T; Ketter TA; Gwizdowski IS; Dennehy EB; Hill SJ; Fischer EG; Snow DE; Gonzalez R; Sureddi S; Shivakumar G; Cosgrove VE
    J Affect Disord; 2013 Aug; 150(1):37-43. PubMed ID: 23521871
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression.
    Suppes T; Datto C; Minkwitz M; Nordenhem A; Walker C; Darko D
    J Affect Disord; 2010 Feb; 121(1-2):106-15. PubMed ID: 19903574
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of quetiapine-XR as monotherapy or adjunctive therapy to a mood stabilizer in acute bipolar depression with generalized anxiety disorder and other comorbidities: a randomized, placebo-controlled trial.
    Gao K; Wu R; Kemp DE; Chen J; Karberg E; Conroy C; Chan P; Ren M; Serrano MB; Ganocy SJ; Calabrese JR
    J Clin Psychiatry; 2014 Oct; 75(10):1062-8. PubMed ID: 25007003
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Self-reported sedation profile of quetiapine extended-release and quetiapine immediate-release during 6-day initial dose escalation in bipolar depression: a multicenter, randomized, double-blind, phase IV study.
    Riesenberg RA; Baldytcheva I; Datto C
    Clin Ther; 2012 Nov; 34(11):2202-11. PubMed ID: 23059166
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term mood/antidepressant effects of quetiapine extended-release formulation: an open-label, non-controlled extension study in Japanese patients with bipolar depression.
    Kanba S; Murasaki M; Koyama T; Takeuchi M; Shimizu Y; Arita E; Kuroishi K; Takeuchi M; Kamei S
    BMC Psychiatry; 2019 Jun; 19(1):198. PubMed ID: 31242884
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.
    Nasrallah HA; Brecher M; Paulsson B
    Bipolar Disord; 2006 Oct; 8(5 Pt 1):467-74. PubMed ID: 17042884
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quetiapine in the treatment of acute bipolar mania: efficacy across a broad range of symptoms.
    McIntyre RS; Konarski JZ; Jones M; Paulsson B
    J Affect Disord; 2007; 100 Suppl 1():S5-14. PubMed ID: 17391773
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A human laboratory study of the effects of quetiapine on subjective intoxication and alcohol craving.
    Ray LA; Chin PF; Heydari A; Miotto K
    Psychopharmacology (Berl); 2011 Oct; 217(3):341-51. PubMed ID: 21487653
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study.
    El-Khalili N; Joyce M; Atkinson S; Buynak RJ; Datto C; Lindgren P; Eriksson H
    Int J Neuropsychopharmacol; 2010 Aug; 13(7):917-32. PubMed ID: 20175941
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group.
    Small JG; Hirsch SR; Arvanitis LA; Miller BG; Link CG
    Arch Gen Psychiatry; 1997 Jun; 54(6):549-57. PubMed ID: 9193196
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparisons of the tolerability and sensitivity of quetiapine-XR in the acute treatment of schizophrenia, bipolar mania, bipolar depression, major depressive disorder, and generalized anxiety disorder.
    Wang Z; Kemp DE; Chan PK; Fang Y; Ganocy SJ; Calabrese JR; Gao K
    Int J Neuropsychopharmacol; 2011 Feb; 14(1):131-42. PubMed ID: 20875219
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quetiapine decreases alcohol consumption, craving, and psychiatric symptoms in dually diagnosed alcoholics.
    Martinotti G; Andreoli S; Di Nicola M; Di Giannantonio M; Sarchiapone M; Janiri L
    Hum Psychopharmacol; 2008 Jul; 23(5):417-24. PubMed ID: 18425995
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of quetiapine extended release monotherapy in bipolar depression: a multi-center, randomized, double-blind, placebo-controlled trial.
    Li H; Gu N; Zhang H; Wang G; Tan Q; Yang F; Ning Y; Zhang H; Lu Z; Xu X; Shi J; Gao C; Li L; Zhang K; Tian H; Wang X; Li K; Li H; Xu Y; Xie S; Yu X
    Psychopharmacology (Berl); 2016 Apr; 233(7):1289-97. PubMed ID: 26911380
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study).
    Weisler RH; Nolen WA; Neijber A; Hellqvist A; Paulsson B;
    J Clin Psychiatry; 2011 Nov; 72(11):1452-64. PubMed ID: 22054050
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of agitation and aggression in bipolar mania: efficacy of quetiapine.
    Buckley PF; Paulsson B; Brecher M
    J Affect Disord; 2007; 100 Suppl 1():S33-43. PubMed ID: 17376537
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.